Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Influx HealthtechNSE:INFLUX +2.55%21 PB Ratio is 6.82 as of Aug. 13, 2026, which is 37% below its 10-year median of 10.90. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review. Among 920 Drug Manufacturers companies, Influx Healthtech ranks worse than 88.26% on this metric.
The historical rank and industry rank for Influx Healthtech's PB Ratio or its related term are showing as below:
NSE:INFLUX'
s PB Ratio Range Over the Past 10 Years
Min: 4.69 Med: 10.9 Max: 15.17
Current: 6.83
During the past 5 years, Influx Healthtech's highest PB Ratio was 15.17. The lowest was 4.69. And the median was 10.90.
NSE:INFLUX's PB Ratio is ranked worse than 88.26% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.99
vs NSE:INFLUX: 6.83
During the past 12 months, Influx Healthtech's average Book Value Per Share Growth Rate was 193.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 108.90% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Influx Healthtech was 108.90% per year. The lowest was 100.90% per year. And the median was 104.90% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Influx Healthtech PB Ratio Related Terms
Influx Healthtech PB Ratio Historical Data
* Premium members only.
The historical data trend for Influx Healthtech's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Influx Healthtech's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Influx Healthtech PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Influx Healthtech's PB Ratio distribution charts can be found below:
* The bar in red indicates where Influx Healthtech's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Influx Healthtech (NSE:INFLUX) has a PB Ratio of 6.82 as of Aug. 13, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Influx Healthtech and its competitors. This is 37% below median its historical median of 10.90. Over the past decade, Influx Healthtech's PB Ratio has ranged from 4.69 to 15.17. According to the industry distribution chart, Influx Healthtech ranks #812 out of 920 companies in the Drug Manufacturers industry, placing it in the top 88.3%.
Is Influx Healthtech's PB Ratio too high?
Influx Healthtech's current PB Ratio of 6.82 is 37% below median its 10-year median of 10.90. Over the past 10 years, this metric has ranged from a low of 4.69 to a high of 15.17. The Drug Manufacturers industry median PB Ratio is 1.99. Influx Healthtech's value of 6.82 is 242.7% above this industry median. Based on the distribution chart, Influx Healthtech ranks #812 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Influx Healthtech ranks #812 out of 920 companies for PB Ratio. This places Influx Healthtech in the lower half of its industry. The industry median PB Ratio is 1.99. Influx Healthtech's value of 6.82 is 242.7% above this benchmark. Historically, Influx Healthtech's own PB Ratio has ranged from 4.69 to 15.17 over the past decade. While the company's 10-year median is 10.90 vs. the industry median of 1.99, Influx Healthtech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.99, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Influx Healthtech's current PB Ratio of 6.82 is 242.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Influx Healthtech and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Influx Healthtech's current PB Ratio is 6.82, which is 37% below median its own 10-year median of 10.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current PB Ratio of 6.82. The current PB Ratio is 6.82, which is 37% below median its 10-year median of 10.90 and 242.7% above the Drug Manufacturers industry median of 1.99. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current PB Ratio is 6.82 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score
Get the complete analysis for NSE:INFLUX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:INFLUX has been successfully added to your 
